Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 2:12:702547.
doi: 10.3389/fgene.2021.702547. eCollection 2021.

Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle

Collaborators, Affiliations
Review

Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle

Olivier Boyer et al. Front Genet. .

Abstract

This article will review myogenic cell transplantation for congenital and acquired diseases of skeletal muscle. There are already a number of excellent reviews on this topic, but they are mostly focused on a specific disease, muscular dystrophies and in particular Duchenne Muscular Dystrophy. There are also recent reviews on cell transplantation for inflammatory myopathies, volumetric muscle loss (VML) (this usually with biomaterials), sarcopenia and sphincter incontinence, mainly urinary but also fecal. We believe it would be useful at this stage, to compare the same strategy as adopted in all these different diseases, in order to outline similarities and differences in cell source, pre-clinical models, administration route, and outcome measures. This in turn may help to understand which common or disease-specific problems have so far limited clinical success of cell transplantation in this area, especially when compared to other fields, such as epithelial cell transplantation. We also hope that this may be useful to people outside the field to get a comprehensive view in a single review. As for any cell transplantation procedure, the choice between autologous and heterologous cells is dictated by a number of criteria, such as cell availability, possibility of in vitro expansion to reach the number required, need for genetic correction for many but not necessarily all muscular dystrophies, and immune reaction, mainly to a heterologous, even if HLA-matched cells and, to a minor extent, to the therapeutic gene product, a possible antigen for the patient. Finally, induced pluripotent stem cell derivatives, that have entered clinical experimentation for other diseases, may in the future offer a bank of immune-privileged cells, available for all patients and after a genetic correction for muscular dystrophies and other myopathies.

Keywords: cell transplantation; inflammatory myopathies; mitochondrial myopathies; muscle stem cells; muscular dystrophies; sphincter incontinence; volumetric muscle loss.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
A simplified scheme of the different cell types (only few examples are shown) available for transplantation in different muscle disorders.

References

    1. Aghajanian H., Kimura T., Rurik J. G., Hancock A. S., Leibowitz M. S., Li L., et al. (2019). Targeting cardiac fibrosis with engineered T cells. Nature 573 430–433. - PMC - PubMed
    1. Ahmed S. T., Craven L., Russel O. M., Turnbull D. M., Vincent A. E. (2018). Diagnosis and treatment of mitochondrial myopathies. Neurotherapeutics 15 943–953. 10.1007/s13311-018-00674-4 - DOI - PMC - PubMed
    1. Albini S., Coutinho P., Malecova B., Giordani L., Savachenko A., Forcales S. V., et al. (2013). Epigenetic reprogramming of human embryonic stem cells into skeletal muscle cells and generation of contractile myospheres. Cell Rep. 3 661–670. 10.1016/j.celrep.2013.02.012 - DOI - PMC - PubMed
    1. Alexander M. S., Rozkalne A., Colletta A., Spinazzola J. M., Johnson S., Rahimov F., et al. (2016). CD82 is a marker for prospective isolation of human muscle satellite cells and is linked to muscular dystrophies. Cell Stem Cell 19 800–807. 10.1016/j.stem.2016.08.006 - DOI - PMC - PubMed
    1. Allen D. G., Whitehead N. P., Froehner S. C. (2015). Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol. Rev. 96 253–305. 10.1152/physrev.00007.2015 - DOI - PMC - PubMed